SDF-1 binding nucleic acids and the use thereof in cancer treatment

US10093934B2 · kind B2 · utility

Assignee

• NOXXON Pharma AG · DE

Inventors

• Werner Purschke · Berlin, DE
• Florian Jarosch · Berlin, DE
• Dirk Eulberg · Berlin, DE
• Sven Klussmann · Berlin, DE
• Klaus Buchner · Schaffhausen, CH
• Christian Maasch · Berlin, DE
• Nicole Dinse · Berlin, DE
• Dirk Zboralski · Berlin, DE

Key dates

• Filing date: Jul 3, 2016
• Grant date: Oct 9, 2018
• Expiry date: Jul 3, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.